Adi F. Gazdar

Oncology · 2001–2019

A researcher in the Science corpus: 21 papers; trusts 8 researchers and is trusted by 8 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 159 citations into it; #401 of 1,698 by trust here, #191 by citations
• Pulmonary and Respiratory Medicine — 152 citations into it; #107 of 770 by trust here, #64 by citations
• Molecular Biology — 137 citations into it; #6,086 of 17,773 by trust here, #914 by citations
• Hematology — 23 citations into it

Whom Adi F. Gazdar trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. William Pao
2. H. Shigematsu
3. T. Kosaka
4. Vincent A. Miller
5. M. Kris
6. C. Sawyers
7. Gregory Riely

Who trusts Adi F. Gazdar overall

1. T. Tan
2. Q. H. Miow
3. Yoshio Miki

Papers from Adi F. Gazdar's perspective

Ordered by how strongly the researchers Adi F. Gazdar trusts endorse each paper. Same corpus, a different order for every researcher.

1. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways (Science)
2. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (Journal of Clinical Oncology)
3. Targeted cancer therapy (Nature)
4. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
5. Anticancer drugs: To the rescue? (Nature reviews. Drug discovery)
6. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
7. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor (Science)
8. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (New England Journal of Medicine)
9. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. (Journal of the National Cancer Institute)
10. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. (Cancer Cell)

Their papers

• The Consensus Coding Sequences of Human Breast and Colorectal Cancers (2006) — 2,786 citations
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers (2004) — 3,682 citations
• Characterizing the cancer genome in lung adenocarcinoma (2007) — 1,146 citations
• A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. (2006) — 3,249 citations
• A small cell lung cancer genome reports complex tobacco exposure signatures (2009) — 880 citations
• Lung cancer in never smokers — a different disease (2007) — 1,514 citations
• Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. (2001) — 822 citations
• Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors (2009) — 1,000 citations
• Genomic alterations in cultured human embryonic stem cells (2005) — 648 citations
• SOX2 Is an Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell Carcinomas (2009) — 956 citations
• Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer (2012) — 1,002 citations
• Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers (2006) — 661 citations
• Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data (2019) — 1,052 citations
• Small-cell lung cancer: what we know, what we need to know and the path forward (2017) — 786 citations
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) — 4,028 citations
• Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery (2009) — 802 citations
• High-throughput oncogene mutation profiling in human cancer (2007) — 1,054 citations
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. (2006) — 2,410 citations
• Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. (2005) — 694 citations
• Immortalization of Human Bronchial Epithelial Cells in the Absence of Viral Oncoproteins (2004) — 658 citations